CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02649764
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:33.003441+00:00
Published At: 2023-10-04T00:00:00+00:00
Record Updated At: 2023-10-04
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Chronic Myelomonocytic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent High Risk Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory High Risk Myelodysplastic Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-10-04"
protocolSection.identificationModule.nctId: "NCT02649764"
protocolSection.identificationModule.officialTitle: "Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.